117 related articles for article (PubMed ID: 34331561)
1. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.
Fernandes MR; Rodrigues JCG; Dobbin EAF; Pastana LF; da Costa DF; Barra WF; Modesto AAC; de Assumpção PB; da Costa Silva AL; Dos Santos SEB; Burbano RMR; de Assumpção PP; Dos Santos NPC
Cancer Chemother Pharmacol; 2021 Nov; 88(5):837-844. PubMed ID: 34331561
[TBL] [Abstract][Full Text] [Related]
2. Association of C677T and A1298C
Ramos-Esquivel A; Chinchilla R; Valle M
Anticancer Res; 2020 Aug; 40(8):4263-4270. PubMed ID: 32727753
[TBL] [Abstract][Full Text] [Related]
3. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
4. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.
Sala-Icardo L; Lamana A; Ortiz AM; García Lorenzo E; Moreno Fresneda P; García-Vicuña R; González-Álvaro I
Reumatol Clin; 2017; 13(6):318-325. PubMed ID: 27751863
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
8. Relevance of
Zhong L; Fu Q; Zhou S; Chen L; Peng Q
BMJ Open; 2018 May; 8(5):e020767. PubMed ID: 29804062
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
[TBL] [Abstract][Full Text] [Related]
10. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
11. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
[TBL] [Abstract][Full Text] [Related]
14. Population stratification effect on cancer susceptibility in an admixed population from Brazilian Amazon.
Vieira PC; Burbano RM; Fernandes DC; Montenegro RC; Dos Santos SE; Sortica VA; Assumpção PP; Ribeiro-Dos-Santos ÂK; Carvalho AA; Dos Santos NP
Anticancer Res; 2015 Apr; 35(4):2009-14. PubMed ID: 25862854
[TBL] [Abstract][Full Text] [Related]
15. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
16. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.
Romiti A; Roberto M; D'Antonio C; Onesti CE; Barucca V; Milano A; Gentile G; Lionetto L; Medda E; Mazzuca F; Botticelli A; Falcone R; Simmaco M; Marchetti P
Anticancer Drugs; 2016 Nov; 27(10):1044-9. PubMed ID: 27557140
[TBL] [Abstract][Full Text] [Related]
17. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
[TBL] [Abstract][Full Text] [Related]
19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
20. In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin.
Tsukioka S; Sakamoto E; Tsujimoto H; Nakagawa F; Saito H; Uchida J; Kiniwa M; Fukushima M
Oncol Rep; 2011 May; 25(5):1407-12. PubMed ID: 21380490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
